PEPTIQORE™
Quality DatabaseTirzepatide

PEPTIQORE QUALITY RECORD

Tirzepatide Quality Intelligence

Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide with a C20 fatty diacid side chain. The dual agonism mechanism distinguishes it from selective GLP-1 agonists and introduces additional complexity in impurity profiling and analytical characterization.

GIP/GLP-1 Dual Receptor AgonistType 2 diabetes mellitus; obesityPartial DataCustom Synthesis AvailableCustom Analysis Available

QUALITY RECORD

PQ-PEP-000002

RECORD TYPE

Therapeutic Peptide

PEPTIQORE ID

PQ-PEP-000002

CAS NUMBER

2023788-19-2

MOLECULAR WEIGHT

4813.5 Da

AMINO ACIDS

39

RECORD VERSION

1.0

RECORD COMPLETENESS

IdentityComplete
Impurity DataPartial
Reference MaterialsPartial
Analytical DataPartial
MethodsPartial
LiteratureComplete

IDENTITY

Tirzepatide Identity

Tirzepatide is a 39-amino acid dual GIP and GLP-1 receptor agonist with a C20 fatty diacid side chain attached via a linker to lysine at position 20. The dual receptor agonism mechanism and longer peptide chain introduce additional complexity in synthesis, impurity profiling and analytical characterization relative to selective GLP-1 analogues.

MOLECULAR FORMULA

C₂₂₅H₃₄₈N₄₈O₆₈

CALCULATED MW

4813.5 Da

CAS NUMBER

2023788-19-2

AMINO ACID COUNT

39

QUALITY RISKS

Relevant Quality Pathways

Based on published literature and regulatory data. Not all pathways necessarily occur in every batch. Dual agonist structure introduces additional analytical complexity.

Oxidation

Met oxidation is a relevant degradation pathway

Relevant

Deamidation

Asn/Gln deamidation under stressed conditions

Relevant

Hydrolysis

Fatty acid side chain hydrolysis

Relevant

Isomerization

Asp isomerization

Relevant

Aggregation

Aggregation-related species

Not reported

QUALITY MAP

Tirzepatide Quality Map

Relevant quality pathways and impurity categories. Data completeness varies by category.

Process-Related Impurities

Synthesis, modification, coupling, cleavage or purification

  • Des-fatty acid impurity (loss of C20 side chain)
  • Incompletely modified lysine variants
  • Linker-related impurities

Relevant quality pathways — not all necessarily present in every batch.

Sequence-Related Impurities

Deletion, insertion, truncation and epimeric variants

  • Deletion variants
  • Truncated sequences
  • Epimeric variants

Dual agonist structure introduces additional complexity relative to selective GLP-1 analogues.

Degradation-Related Impurities

Oxidation, deamidation, hydrolysis and other degradation pathways

  • Met oxidation products
  • Asn/Gln deamidation products
  • Fatty acid side chain hydrolysis products

Relevant quality pathways based on published literature.

QUALITY GRAPH

Tirzepatide Knowledge Graph

Connected quality knowledge — not a product catalog.

QUALITY INTELLIGENCE

Analyze Tirzepatide Quality Risk

Use PeptiQore Intelligence to explore degradation pathways, interpret mass shifts, investigate unknown peaks and review impurity strategy for tirzepatide.

COMMERCIAL SUPPORT

Tirzepatide Quality Support

Request Reference Material

Tirzepatide parent or impurity reference material for analytical use.

Request Reference Material

Request Custom Synthesis

Custom synthesis of tirzepatide-related impurities not in the standard catalog.

Request Custom Synthesis

Investigate Unknown Peak

Unexpected chromatographic peak in your tirzepatide sample requiring investigation.

Investigate Unknown Peak

SOURCES & EVIDENCE

REGULATORYPEER-REVIEWEDCOMPENDIALPEPTIQORE EXPERIMENTAL

PeptiQore provides scientific information for professional laboratory, development and quality-control use. Public database content may include literature-derived, regulatory, experimental and computational information. Users should evaluate source and evidence status before applying information to regulated decisions.